ong term survival and complications in patients operated for Prosthetic heart valves on Nicoumalone(Acenocoumarol) and tissue valve outcomes
Not Applicable
- Conditions
- Health Condition 1: I719- Aortic aneurysm of unspecified site, without ruptureHealth Condition 2: Q874- Marfans syndromeHealth Condition 3: I348- Other nonrheumatic mitral valve disordersHealth Condition 4: I06- Rheumatic aortic valve diseasesHealth Condition 5: I05- Rheumatic mitral valve diseasesHealth Condition 6: I089- Rheumatic multiple valve disease,unspecifiedHealth Condition 7: I07- Rheumatic tricuspid valve diseases
- Registration Number
- CTRI/2022/01/039268
- Lead Sponsor
- Abbott Healthcare Pvt Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Patient who underwent prosthetic valve replacement since Jan 1971
2.Patient who were managed by Nicoumalone (Acenocoumarol) after the prosthetic valve replacement and whose dose titration was done based on the INR monitoring
3.Patient with no prior history of MACCE- Stroke, MI, and major bleeding
Exclusion Criteria
1.Patient who underwent Cardiac Surgery other than Prosthetic Valve Replacement, eg. Coronary Artery Bypass Graft Surgery(CABG) etc.
2.Patient who underwent prosthetic valve replacement procedure before Jan 1971
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method